A database of FDA approved therapeutic peptides and proteins
ID1029 | ThPPIDTh1005 | NameEtanercept | Peptide SequenceLPAQVAFTPYAPEPGSTCRL Full view | Length255 | Functional ClassificationIIa | DiseaseImmunological | BrandEnbrel Sureclick | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetTumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
ID1033 | ThPPIDTh1006 | NameBivalirudin | Peptide SequenceFPRPGGGGNGDFEEIPEEYL Full view | Length20 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAngiox | CompanyThe Medicines Company UK Ltd | Physical AppearancePowder for concentrate for solution | Route of AdministartionInjection | CategoryAntithrombins | TargetProthrombin |
ID1039 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandEnantone | CompanyTakeda | Physical AppearanceSolution | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1049 | ThPPIDTh1008 | NamePeginterferon alfa-2a | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandPegasys | CompanyHoffman-La Roche Inc | Physical AppearanceSterile, preservative-free, colorless to light yellow injectable solution | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1059 | ThPPIDTh1010 | NameInterferon alfa-n1 | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseInfectious /Immunological | BrandWellferon | CompanyGlaxoSmithKline | Physical AppearanceSolution | Route of AdministartionInjection | CategoryAntiviral Agents, Immunologic factors, Immunosuppressiv agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1064 | ThPPIDTh1011 | NameDarbepoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandAranesp | CompanyAmgen Inc | Physical AppearanceSterile, colorless, preservative-free solution containing polysorbate | Route of AdministartionIntravenousor Subcutaneous administration | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1071 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandBinocrit | CompanySandoz | Physical AppearanceClear colourless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1076 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEprex | CompanyJanssen-Cilag. Ortho Biologics LLC | Physical AppearanceSolution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1077 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandNanokine | CompanyNanogen Pharmaceutical biotechnology, Vietnam) | Physical AppearanceSterile, white, lyophilized powder. The reconstituted preparation with 1 ml solvent (containing 0.9% benzyl alcohol) results in a clear, colorless solution. | Route of AdministartionInjection | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1078 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandProcrit | CompanyOrtho Biotech | Physical AppearanceSterile, colorless liquid in an isotonic sodium chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate buffered solution | Route of AdministartionIntravenous(IV) or Subcutaneous (SC) administration. | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1098 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandCalcimar | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous or Intramuscular Injection | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1100 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandMiacalcin | CompanyNovartis | Physical AppearanceSolution | Route of AdministartionSubcutaneous or Intramuscular Injection | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1110 | ThPPIDTh1015 | NameInterferon alfa-n3 | Peptide SequenceAlpha-2A:CDLPQTHSLG< Full view | Length235 | Functional ClassificationIb | DiseaseImmunological | BrandAlferon | CompanyInterferon Sciences Inc. | Physical AppearanceSolution | Route of AdministartionInjection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1117 | ThPPIDTh1016 | NamePegfilgrastim | Peptide SequenceMTPLGPASSLPQSFLLKCLE Full view | Length175 | Functional ClassificationIb | DiseaseImmunological | BrandNeulasta | CompanyAmgen Inc. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents, Anti-neutropenic agents | TargetGranulocyte colony-stimulating factor receptor,Neutrophil elastase |
ID1120 | ThPPIDTh1017 | NameSargramostim | Peptide SequenceAPARSPSPSTQPWEHVNAIQ Full view | Length127 | Functional ClassificationIb | DiseaseImmunological | BrandLeucomax | CompanyNovartis | Physical AppearanceSolution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryImmunosuppressive Agents | TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
ID1121 | ThPPIDTh1017 | NameSargramostim | Peptide SequenceAPARSPSPSTQPWEHVNAIQ Full view | Length127 | Functional ClassificationIb | DiseaseImmunological | BrandLeukine | CompanyBerlex Laboratories Inc | Physical AppearanceSterile, preserved (1.1% benzyl alcohol), injectable solution (500 mcg/mL) and also as sterile, white, preservative free lyophilized powder (250 mcg) that requires reconstitution with 1 mL sterile water for Injection | Route of AdministartionSubcutaneous Injection (SC) or Intravenous infusion (IV) | CategoryImmunosuppressive Agents | TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
ID1130 | ThPPIDTh1018 | NameSecretin | Peptide SequenceHSDGTFTSELSRLRDSARLQ Full view | Length27 | Functional ClassificationIV | DiseaseHormonal disorders | BrandSecremax | CompanyRepligen Corp | Physical AppearanceSolution | Route of AdministartionIntravenous | CategoryDiagnostic Agents | TargetSecretin receptor |
ID1157 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandMonoclate-P | CompanyN.A. | Physical AppearanceLyophilized powder for solution | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1180 | ThPPIDTh1023 | NameAnakinra | Peptide SequenceMRPSGRKSSKMQAFRIWDVN Full view | Length153 | Functional ClassificationIIa | DiseaseImmunological | BrandKineret | CompanyAmgen Inc | Physical AppearanceSterile, clear, colorless-to-white, preservative free solution | Route of AdministartionSubcutaneous (SC) administration | CategoryImmunosuppressive Agents, Anti-rheumatic agents | TargetInterleukin-1 receptor type 1 |
ID1188 | ThPPIDTh1024 | NameGramicidin D | Peptide SequenceVGALAVVVWLWLWLWX Full view | Length16 | Functional ClassificationIIa | DiseaseInfectious | BrandSofradex | CompanySanofi | Physical AppearanceSterile, clear, bright, colourless, aqueous solution | Route of AdministartionAuricular and Ocular use. | CategoryAnti-Bacterial Agents, Anti-infective, Topical, Antibiotic | TargetN.A. |
ID1195 | ThPPIDTh1025 | NameIntravenous Immunoglobulin | Peptide SequenceIGG1:PSALTQPPSASGSLG Full view | Length250 | Functional ClassificationIa | DiseaseImmunological | BrandGamunex | CompanyTalecris Biotherapeutics | Physical AppearanceSterile solution | Route of AdministartionIntravenous infusion | CategoryImmunosuppressive Agents, Immunologic factors, Anti-infective agents | TargetHigh affinity immunoglobulin gamma Fc receptor I,High affinity immunoglobulin gamma Fc receptor IB,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc reg |
ID1205 | ThPPIDTh1027 | NameInsulin Regular | Peptide SequenceA-chain:GIVEQCCTSIC< Full view | Length51 | Functional ClassificationIa | DiseaseGenetic/Hormonal | BrandHumulin R | CompanyEli Lilly and Company | Physical AppearanceSterile, clear, aqueous, and colorless solution | Route of AdministartionSubcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm and Intravenousadministration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision. | CategoryAntidiabetic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
ID1206 | ThPPIDTh1027 | NameInsulin Regular | Peptide SequenceA-chain:GIVEQCCTSIC< Full view | Length51 | Functional ClassificationIa | DiseaseGenetic/Hormonal | BrandNovolin R | CompanyNovo Nordisk | Physical AppearanceSterile, clear, aqueous, and colorless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAntidiabetic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
ID1226 | ThPPIDTh1030 | NameInterferon gamma-1b | Peptide SequenceCYCQDPYVKEAENLKKYFNA Full view | Length146 | Functional ClassificationIb | DiseaseImmunological | BrandActimmune | CompanyInterMune Inc | Physical AppearanceSterile, clear, colorless solution | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents | TargetInterferon gamma receptor 1,Interferon gamma receptor 2 |
ID1229 | ThPPIDTh1031 | NameInterferon Alfa-2a, Recombinant | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandRoferon A | CompanyHoffmann-La Roche Inc | Physical AppearanceSolution | Route of AdministartionSubcutaneous Injection | CategoryN.A. | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1260 | ThPPIDTh1037 | NameBotulinum Toxin Type B | Peptide SequenceMPVTINNFNYNDPIDNNNII Full view | Length255 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandMyobloc | CompanySolstice Neurosciences | Physical AppearanceClear and colorless to light-yellow sterile injectable solution | Route of AdministartionInjection | CategoryAntidystonic Agents | TargetVesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
ID1261 | ThPPIDTh1037 | NameBotulinum Toxin Type B | Peptide SequenceMPVTINNFNYNDPIDNNNII Full view | Length255 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandNeurobloc | CompanySolstice Neurosciences | Physical AppearanceClear and colourless to light yellow solution | Route of AdministartionIntramuscular Injection | CategoryAntidystonic Agents | TargetVesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
ID1269 | ThPPIDTh1039 | NameLutropin alfa | Peptide SequenceAlpha Chain: APDVQDC Full view | Length213 | Functional ClassificationIb | DiseaseHormonal | BrandLuveris | CompanySerono | Physical AppearanceWhite lyophilised pellet withg clear colourless solvent to make solution | Route of AdministartionSubcutaneous (SC) administration | CategoryFertility Agents | TargetLutropin-choriogonadotropic hormone receptor |
ID1275 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog | CompanyEli Lilly | Physical AppearanceSterile, aqueous, clear, and colorless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1276 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog KwikPen | CompanyEli Lilly | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1283 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus | CompanySanofi-Aventis | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1284 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus OptiSet | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1285 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus SoloStar | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1306 | ThPPIDTh1043 | NameRasburicase | Peptide SequenceSAVKAARYGKDNVRVYKVHK Full view | Length255 | Functional ClassificationIc | DiseaseMetabolic/Genetic | BrandFasturtec | CompanyN.A. | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionIntravenous administartion | CategoryAntihyperuricemic Agents, Gout suppressants | TargetUric acid |
ID1316 | ThPPIDTh1044 | NameAdalimumab | Peptide SequenceLight-chain:DIQMTQS< Full view | Length230 | Functional ClassificationIc | DiseaseImmunological | BrandHumira | CompanyAbbott Laboratories | Physical AppearanceSterile, preservative-free solution | Route of AdministartionSubcutaneous administration | CategoryImmunosuppressive Agents, Anti-inflammatory, Antirheumatic agents | TargetTumor necrosis factor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamm |
ID1317 | ThPPIDTh1044 | NameAdalimumab | Peptide SequenceLight-chain:DIQMTQS< Full view | Length230 | Functional ClassificationIc | DiseaseOsteological | BrandHumira Pen | CompanyAbbott Laboratories | Physical AppearanceSterile, preservative-free solution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents, Anti-inflammatory, Antirheumatic agents | TargetTumor necrosis factor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamm |
ID1327 | ThPPIDTh1046 | NameAbciximab | Peptide SequenceH ReoPro-like antibo Full view | Length218 | Functional ClassificationIIa | DiseaseGenetic/Metabolic/Haemetological | BrandReoPro | CompanyEli Lilly and Company | Physical AppearanceClear, colorless, sterile, non-pyrogenic solution | Route of AdministartionIntravenous administartion | CategoryPlatelet Aggregation Inhibitors, Anticoagulants | TargetIntegrin beta-3,Integrin alpha-IIb,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immuno |
ID1337 | ThPPIDTh1048 | NamePegaspargase | Peptide SequenceMEFFKKTALAALVMGFSGAA Full view | Length255 | Functional ClassificationIc | DiseaseCancer | BrandOncaspar | CompanyEnzon Inc | Physical AppearanceSolution | Route of AdministartionIntravenous or Intramuscular administration | CategoryAntineoplastic Agents | TargetL-asparagine |
ID1342 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBetaferon | CompanyBayer | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1346 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandRebif | CompanyMerck | Physical AppearanceSterile solution in a prefilled syringe or REBIF Rebidose autoinjector | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1358 | ThPPIDTh1050 | NamePegademase bovine | Peptide SequenceMAQTPAFNKPKVELHVHLDG Full view | Length255 | Functional ClassificationIa | DiseaseMetabolic | BrandAdagen | CompanyEnzon Inc. | Physical AppearanceIsotonic, pyrogen free, sterile solution, pH 7.2-7.4 | Route of AdministartionIntramusular Injection | CategoryEnzyme Replacement Agents | TargetAdenosine,Growth factor receptor-bound protein 2 |
ID1361 | ThPPIDTh1051 | NameHuman Serum Albumin | Peptide SequenceMKWVTFISLLFLFSSAYSRG Full view | Length609 | Functional ClassificationIa | DiseaseHematological/Metabolic/genetic | BrandAlbuminar | CompanyCSL Behring | Physical AppearanceSterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled fractionation according to the Cohn process. | Route of AdministartionAlbumin (Human) 25%, Albuminar-25 (albumin human) , is to be administered by the Intravenous route. | CategorySerum substitutes | TargetN.A. |
ID1362 | ThPPIDTh1051 | NameHuman Serum Albumin | Peptide SequenceMKWVTFISLLFLFSSAYSRG Full view | Length609 | Functional ClassificationIa | DiseaseHematological/Metabolic/genetic | BrandAlbutein | CompanyGRIFOLS | Physical AppearanceSterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). | Route of AdministartionAlbutein 20% is to be administered by the Intravenous route. | CategorySerum substitutes | TargetN.A. |
ID1363 | ThPPIDTh1052 | NameEptifibatide | Peptide SequenceMpr-Har-Gly-Asp-Trp- Full view | Length7 | Functional ClassificationIb | DiseaseHematological/Metabolic | BrandINTEGRILIN | CompanySchering-Plough/Essex | Physical AppearanceClear, colorless, sterile, non-pyrogenic solution of Eptifibatide | Route of AdministartionInjection Solution for IIntravenousUse | CategoryPlatelet Aggregation Inhibitors | TargetLutropin-choriogonadotropic hormone receptor,Follicle-stimulating hormone receptor |
ID1365 | ThPPIDTh1053 | NameSerum albumin iodonated | Peptide SequenceMKWVTFISLLFLFSSAYSRG Full view | Length600 | Functional ClassificationIV | DiseaseHematological Disorders | BrandMegatope | CompanyIsoTex Diagnostics | Physical AppearanceColorless to very pale yellow solutions | Route of AdministartionInjection for Intravenous administration | CategoryDiagnostic Agents | TargetApolipoprotein E,Serum amyloid A-1 protein,Protein AMBP |
ID1366 | ThPPIDTh1053 | NameSerum albumin iodonated | Peptide SequenceMKWVTFISLLFLFSSAYSRG Full view | Length600 | Functional ClassificationIV | DiseaseHematological Disorders | BrandJeanotope | CompanyIsoTex Diagnostics | Physical AppearanceSterile, nonpyrogenic, aqueos solution | Route of AdministartionIntravenous infusion | CategoryDiagnostic Agents | TargetApolipoprotein E,Serum amyloid A-1 protein,Protein AMBP |
ID1372 | ThPPIDTh1055 | NameFollitropin beta | Peptide SequenceA Chain: APDVQDCPECT Full view | Length204 | Functional ClassificationIb | DiseaseHormonal disorders | BrandFollistim AQ | CompanyMerck | Physical AppearanceSterile aqueous solution | Route of AdministartionSubcutaneous or Intramuscular administration | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor |
ID1375 | ThPPIDTh1056 | NameVasopressin | Peptide SequenceCYFQNCPRG Full view | Length9 | Functional ClassificationIb | DiseaseHormonal | BrandPitressin | CompanyJHP Pharmaceuticals | Physical AppearanceSterile, aqueous solution of synthetic vasopressin | Route of AdministartionIntramuscular or Subcutaneous use | CategoryAntidiuretic Agents | TargetVasopressin V2 receptor,Vasopressin V1a receptor,Vasopressin V1b receptor |
ID1377 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandBetaferon | CompanyBayer | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1381 | ThPPIDTh1059 | NameHyaluronidase | Peptide SequenceMWTGLGPAVTLALVLVVAWA Full view | Length476 | Functional ClassificationIc | DiseaseAdjunct Therapy | BrandHYLENEX | CompanyBaxter Healthcare Corporation | Physical AppearanceSterile, clear, colorless, nonpreserved, ready for use solution. | Route of AdministartionHuman Injection Subcutaneous use | CategoryAdjuvants, Anesthesia and Permeabilizing Agents | TargetN.A. |